Table 1.

Baseline characteristics.

	KIT–11 (n = 24)	KIT–9 (n = 11)
Age, year	54.75 ± 13.57	53.27 ± 12.07
Male, n (%)	19 (79.2%)	7 (63.6%)
Symptomatic at presentation, n (%)	16 (66.7%)	11 (100%)*
Risk classification, n (%)
Low risk	5 (20.8%)	1 (9.1%)
Intermediate risk	3 (12.5%)	2 (18.2%)
High risk	16 (66.7%)	8 (72.7%)
Immunohistochemical analysis
CD117, n (%)	24 (100%)	11 (100%)
Dog-1, n (%)	24 (100%)	11 (100%)
CD34, n (%)	13 (54.2%)	8 (72.7%)
S-100, n (%)	1 (4.2%)	1 (9.1%)
SMA, n (%)	11 (45.8%)	4 (36.4%)
Ki-67, %	7.30 ± 3.88	9.30 ± 7.01*

Values are presented as mean ± standard deviation or numbers (percentages).

*Means P < 0.05 versus KIT–11 group.